Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Tumors with inherited or somatic deficiencies in HRR genes, such as BRCA1, BRCA2, PALB2, and RAD51, exhibit synthetic lethality to PARPis, including olaparib, rucaparib, niraparib, and talazoparib, which have shown durable efficacy in BRCA-mutant breast, ovarian, and prostate cancers
Benefits : This innovative product is made from safe and natural ingredients
PubMed Brown BG, Zhao XQ, Chait A, et al
M.TalwarM.ColemanC
US$ 24.69
US$ 21.17
US$ 29.83
US$ 24.51
US$ 26.32
US$ 29.75
